Given a paragraph, generate a claim that is supported by the given paragraph. 1) The claim must contain information from within the paragraph. 2) A sentence within the paragraph can be used as a claim. 3) The claim should not have contradictions within the paragraph. 4) The claim should be at most one sentence long.

Input: Consider Input: Wisconsin Department of Natural Resources records show that Tyco Fire Products discovered soil and well contamination on the Marinette manufacturer’s fire training property in 2013, the Milwaukee Journal-Sentinel reported. The contamination involves a class of chemicals known as per- and polyfluoroalkyl substances, or PFAS, which are linked to cancer and other health issues. The company was found to have some of the highest known concentrations of the chemicals in groundwater and soil in Wisconsin, according to the records. In November 2017, Tyco, a Johnson Controls International unit, acknowledged that the chemicals had spread beyond its Marinette facility and suspended spraying foam products outdoors. The following month, the company started distributing bottled water to residents whose private wells may be affected by the contamination. Tyco tested 168 wells and 56 have shown evidence of the chemicals, the company said. State officials said Wisconsin law requires companies to immediately report pollution , but the company defended its actions by saying that little was known about PFAS at the time. “In 2013, there was not the level of awareness and information as there is today associated with PFOS/PFOA,” said Fraser Engerman, a spokesman for Johnson Controls International. But scientists have warned about the health impacts and other companies have phased out production of the chemicals for more than a decade. Tyco has also claimed that the company didn’t know about contamination beyond the property until 2016. “It wasn’t until 2016 that we had data that showed we had concentrations of these compounds at the edge of the property, so we then began the series of tests which led us to where we are today,” the company’s website states. Doug Oitzinger, the city’s former mayor, dismissed Tyco’s explanation. “This isn’t news to them,” he said. “They know that these pollutants have been judged an environmental danger .” Janell and Duane Goldsmith have twice tested their well water and found chemical contamination above the federal health advisory threshold. Duane Goldsmith has been diagnosed with gastrointestinal stromal tumor cancer and Janell Goldsmith had pregnancy-induced high blood pressure, according to a lawsuit filed in December. The couple’s two sons also have had developmental delays, the lawsuit states. “They’ve known about this for how long — and they have been using these chemicals?” Janell Goldsmith said. “You don’t expect it to happen to your family and to your community. So much crosses your mind.” ___ Information from: Milwaukee Journal Sentinel, http://www.jsonline.com

Output: Records: Tyco knew of contamination 4 years before reporting.


Input: Consider Input: Luke Miels, who joined GSK in September 2017 after a contract dispute with his former employer AstraZeneca, said picking the most promising projects and developing them quickly now takes precedence over spreading the risk of failure. “In the past, 10 programs were chosen, a budget for eight was allocated. Usually what happened was that time was the trade off that was made,” he said in an interview. “Now what we do is we pick five or six programs, and concentrate investment there.”   GSK, like rivals, was in the habit of testing new drugs first on patients who had run out of other treatment options. If successful, it would try patients at an earlier stage of their disease, replacing older, established treatments. In today’s market, where rivals in the United States and China catch up fast if a new class of drug shows promise, GSK has to run costly drug tests on humans in several settings at the same time, even if it means dropping other drug candidates. “Rather than do things sequentially, you do them in parallel, or as close to parallel as possible,” Miels said. GSK, which is battling to return to profit growth, has taken this approach for instance with an experimental drug that for now goes by the code name of GSK’916 against multiple myeloma, a common and incurable type of blood cancer. Likewise, GSK doubled down on its quest to bring a drug known as GSK’165 to market as a rheumatoid arthritis treatment, even after initial results in a mid-stage drug trial did not show a clear enough reading. “This drug has very interesting effects on pain. That could potentially reduce the use of opioids and pain meds,” Miels said. More trials will be run to make the pain argument more clearly, he added. GSK expects a decline of 5%-9% in adjusted earnings per share this year, excluding exchange rate moves, as it suffers from generic competition to its inhalable lung drug Advair and pressure from rival Gilead in HIV treatments. Miels said a tougher stance on drug prices by U.S. lawmakers and medical insurers was one of the reasons for the need for speed in bringing drugs to market - to try to remain ahead of competitors for as long as possible. At the same time, rapid growth in the Chinese market was spurring a more sophisticated healthcare system there, with local biotech groups quick to catch up with Western pioneers in drug development, producing similar drugs for their home market.

Output: GSK pharma head flags need for speed in high-pressure drug market.


Input: Consider Input: Brattleboro Retreat Board Chair Elizabeth Catlin said the organization is ready to work “with all willing partners” to help it achieve financial stability. The board began considering its options last week when the state of Vermont rejected a $2 million request for additional funding. “In recent years, the Brattleboro Retreat’s board and its management team have taken a number of creative, cost-conscious steps to reshape and modernize hospital operations while meeting the rising tide of soaring labor costs,” said Catlin’s statement. “The Brattleboro Retreat’s quality of care, even with these financial pressures, continues to be excellent.”   The facility serves more than half the people in Vermont who need psychiatric care and provides all of the child and adolescent psychiatric care in the state. It also provides addiction services including inpatient and outpatient rehabilitation, and treatment services for those who get Suboxone, a prescription medication used to treat opioid addictions. If it closes, the letter said that would mean finding services for 2,500 inpatients annually as well as filling new gaps for Suboxone treatment services, residential programs for children and meeting other critical health needs. On Sunday, Vermont Human Services Secretary Michael Smith said he had rejected a request for an additional $2 million in funding from the retreat. That request would be added to a financial package valued at an estimated $16 million for new beds and a recent rate increase valued at an estimated $3.5 million per year. Smith said he rejected the request in part because he believes it would constitute a taxpayer bailout of financial miscalculations by Brattleboro Retreat’s management. But Josephson said the state wasn’t paying it enough to care for the patients the state wants cared for. On Friday, Josephson sent a letter Friday to Smith and Gov. Phil Scott, a Republican, that said the facility cannot continue operating without more support from the state. He said the board had authorized him to begin planning for the sale or closure of the retreat “in the very near future.”


Output: Psych hospital’s financial woes won’t stop services, for now.